![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF529 |
Gene summary for ZNF529 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF529 | Gene ID | 57711 |
Gene name | zinc finger protein 529 | |
Gene Alias | ZNF529 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6P280 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57711 | ZNF529 | male-WTA | Human | Thyroid | PTC | 2.35e-09 | 4.07e-02 | 0.1037 |
57711 | ZNF529 | PTC01 | Human | Thyroid | PTC | 7.42e-05 | -7.90e-03 | 0.1899 |
57711 | ZNF529 | PTC04 | Human | Thyroid | PTC | 3.79e-06 | 1.12e-01 | 0.1927 |
57711 | ZNF529 | PTC05 | Human | Thyroid | PTC | 2.78e-07 | 2.15e-01 | 0.2065 |
57711 | ZNF529 | PTC06 | Human | Thyroid | PTC | 1.53e-10 | 1.90e-01 | 0.2057 |
57711 | ZNF529 | PTC07 | Human | Thyroid | PTC | 3.00e-15 | 9.40e-02 | 0.2044 |
57711 | ZNF529 | ATC12 | Human | Thyroid | ATC | 5.89e-03 | -2.12e-02 | 0.34 |
57711 | ZNF529 | ATC13 | Human | Thyroid | ATC | 1.23e-61 | 1.30e+00 | 0.34 |
57711 | ZNF529 | ATC2 | Human | Thyroid | ATC | 2.64e-04 | 3.29e-01 | 0.34 |
57711 | ZNF529 | ATC4 | Human | Thyroid | ATC | 1.75e-06 | -5.30e-06 | 0.34 |
57711 | ZNF529 | ATC5 | Human | Thyroid | ATC | 9.28e-77 | 1.39e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF529 | SNV | Missense_Mutation | c.858N>G | p.Phe286Leu | p.F286L | Q6P280 | protein_coding | deleterious(0.01) | benign(0.153) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
ZNF529 | SNV | Missense_Mutation | novel | c.661N>A | p.His221Asn | p.H221N | Q6P280 | protein_coding | deleterious(0) | possibly_damaging(0.72) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
ZNF529 | SNV | Missense_Mutation | c.844N>G | p.Phe282Val | p.F282V | Q6P280 | protein_coding | deleterious(0) | benign(0.167) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF529 | SNV | Missense_Mutation | novel | c.761N>C | p.Tyr254Ser | p.Y254S | Q6P280 | protein_coding | deleterious(0) | possibly_damaging(0.737) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF529 | SNV | Missense_Mutation | novel | c.401N>T | p.Pro134Leu | p.P134L | Q6P280 | protein_coding | tolerated(0.41) | benign(0.045) | TCGA-DS-A7WI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ZNF529 | SNV | Missense_Mutation | c.235N>T | p.Asp79Tyr | p.D79Y | Q6P280 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF529 | SNV | Missense_Mutation | c.1495A>G | p.Ile499Val | p.I499V | Q6P280 | protein_coding | tolerated(0.08) | possibly_damaging(0.73) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ZNF529 | SNV | Missense_Mutation | c.463C>A | p.His155Asn | p.H155N | Q6P280 | protein_coding | tolerated(0.15) | benign(0.006) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF529 | SNV | Missense_Mutation | novel | c.84C>A | p.Phe28Leu | p.F28L | Q6P280 | protein_coding | tolerated(0.14) | benign(0.024) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF529 | SNV | Missense_Mutation | c.1493G>T | p.Arg498Ile | p.R498I | Q6P280 | protein_coding | deleterious(0.02) | probably_damaging(0.939) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |